Molina Healthcare, Encompass Health, RadNet, Evolent Health, and Ibotta Shares Are Falling, What You Need To Know What Happened? A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth. Trump's comments added pressure to an already sensitive market, raising concerns about political interference in monetary policy. Meanwhile, Fed Chair Jerome Powell maintained a cautious stance the previous week, highlighting the difficulty of balancing the dual mandate of steady employment and price stability amid the escalating trade tension. Investor sentiment was further dampened by the absence of constructive progress in trade negotiations, especially US-China relations which took a turn for the worse in the previous week. Overall, the outlook seemed more unclear heading into the first quarter 2025 earnings season, as a combination of hard to predict monetary policy and unresolved trade tensions weighed on business confidence. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, following stocks were impacted: Health Insurance Providers company Molina Healthcare (NYSE:MOH) fell 5.3%. Is now the time to buy Molina Healthcare? Access our full analysis report here, it’s free. Outpatient & Specialty Care company Encompass Health (NYSE:EHC) fell 6%. Is now the time to buy Encompass Health? Access our full analysis report here, it’s free. Testing & Diagnostics Services company RadNet (NASDAQ:RDNT) fell 5%. Is now the time to buy RadNet? Access our full analysis report here, it’s free. Healthcare Technology for Providers company Evolent Health (NYSE:EVH) fell 5.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it’s free. Advertising & Marketing Services company Ibotta (NYSE:IBTA) fell 5%. Is now the time to buy Ibotta? Access our full analysis report here, it’s free. Zooming In On Encompass Health (EHC) Encompass Health’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. Encompass Health is up 4.6% since the beginning of the year, and at $96.12 per share, it is trading close to its 52-week high of $103.77 from November 2024. Investors who bought $1,000 worth of Encompass Health’s shares 5 years ago would now be looking at an investment worth $1,426. Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. View Comments
Molina Healthcare, Encompass Health, RadNet, Evolent Health, and Ibotta Shares Are Falling, What You Need To Know
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...